R&D Pipeline

Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.

Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.

Bempegaldesleukin in combination with OPDIVO® (nivolumab)

Indication: Muscle-invasive Bladder Cancer

Partner
Partner

Phase 3

NKTR-358

INDICATION: Systemic Lupus Erythematosus

Discovered by Nektar

Partner
Partner

Phase 2

Dapirolizumab Pegol (Anti-CD40L)

Indication: Systemic lupus erythematosus (SLE)

Partner
Partner

In partnership with Partner

Phase 2

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that occurs when the body's own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (Anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in SLE patients. Dapirolizumab pegol is being developed by Biogen and UCB, Inc. in a Phase 2 clinical trial to evaluate the efficacy and safety of dapirolizumab pegol in patients with moderately to severely active systemic lupus erythematosus. For more information about this study, visit clinicaltrials.gov.

NKTR-255 monotherapy and in Combination with Rituxan© (rituximab) or Darzalex Faspro© (daratumumab)

INDICATION: Non-Hodgkin’s Lymphoma and Multiple Myeloma

Discovered and wholly owned by Nektar

Unpartnered

Phase 2

NKTR-255 is a memory T cell stimulating cytokine designed to engage the IL-15 pathway to enhance and sustain long-term T cell memory response to treat cancer.

NKTR-255 in combination with Erbitux© (cetuximab) in Solid Tumors

INDICATION: Head and Neck Cancer and Colorectal Cancer

Discovered and wholly owned by Nektar

Unpartnered

Phase 2

Bempegaldesleukin in combination with VB10.NEO

Indication: Squamous Cell Carcinoma of the Head and Neck

In clinical collaboration with Collaborator

Phase 1/2A

NKTR-358

INDICATION: Psoriasis

Discovered by Nektar

Partner
Partner

Phase 1B

NKTR-358

INDICATION: Atopic Dermatitis

Discovered by Nektar

Partner
Partner

Phase 1B

Bempegaldesleukin in combination with KEYTRUDA® (pembrolizumab)

Indication: Non-Small Cell Lung Cancer

Discovered and wholly owned by Nektar

Unpartnered

Phase 1/2

NKTR-262 in combination with bempegaldesleukin

INDICATION: Locally Advanced or Metastatic Solid Tumor Malignancies

Discovered and wholly owned by Nektar

Unpartnered

Phase 1

Bempegaldesleukin

Indication: COVID-19

Unpartnered

Phase 1B

*Planned registrational study